Overall, the findings from testing PPARs’ natural agonists (such as FAs, flavonoids, curcumin, and others) in various neurological disorders support PPAR-γ, PPAR-α, and PPAR-β (few studies) as potential novel targets for the therapeutic management of common and debilitating conditions such as AD and PD. This evidence concerns the gene PPARG and Parkinson disease.